1. 1897PDDifferential expression of immune checkpoints (PD-L1, HHLA2, B7x and B7H3) and their association with driver mutations in pulmonary sarcomatoid carcinoma (PSC). (23rd October 2018) Authors: Cheng, H; Sharma, J; Su, C; Li, S; Zang, X; Perez-Soler, R; Halmos, B; Borczuk, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A199 EFFICACY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: RESULTS FROM THE OCTAVE CLINICAL TRIALS. (1st March 2018) Authors: Panés, J; Bressler, B; Colombel, J F; Lawendy, N; Maller, E; Zhang, H; Woodworth, D; Chan, G; Su, C Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS. (15th March 2019) Authors: Sandborn, W J; Panés, J; Panaccione, R; D'Haens, G; Sands, B E; Su, C; Moscariello, M; Jones, T V; Pedersen, R D; Friedman, G S; Lawendy, N; Chan, G Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 2(2019)Supplement 2 Page Start: 396 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Analysis of Impact of Distributed Photovoltaic on Main Transformer Gap Protection. Issue 1 (1st February 2022) Authors: Tian, G; Yan, P; Hu, X K; Luo, P; Su, C; Zhang, Q Journal: Journal of physics Issue: Volume 2186:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AODWE-004 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis. (17th June 2017) Authors: Panés, J; Rubin, DT; Vermeire, S; Lindsay, JO; Sands, BE; Su, C; Friedman, G; Zhang, H; Kayhan, C; Manuchehri, A; Healey, P Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Design of piezoelectric self-sensing microinjection device. (April 2019) Authors: Wei, X W; Sun, L P; Su, C; Shi, Y L; Li, J Q Journal: Journal of physics Issue: Volume 1209(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. DOP023 Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials. (16th January 2018) Authors: Sandborn, W J; Panés, J; D'Haens, G R; Sands, B E; Su, C; Moscariello, M; Jones, T V; Pedersen, R D; Friedman, G S; Lawendy, N; Chan, G Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S045 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open. (16th January 2018) Authors: Sands, B E; Moss, A C; Armuzzi, A; Marshall, J K; Lindsay, J O; Sandborn, W J; Danese, S; Tsilkos, K; Lawendy, N; Zhang, H; Friedman, G S; Chan, G; Krichbaum, D W; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. DOP027 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders. (16th January 2018) Authors: Feagan, B G; Dubinsky, M C; Lukas, M; Quirk, D; Nduaka, C I; Maller, E; Lawendy, N; Kayhan, C; Wang, W; Chan, G; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S050 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies. (25th January 2019) Authors: Chiorean, M; Su, C; Matsuoka, K; Orlando, A; Thorpe, A J; Nduaka, C I; Chapman, D S; Woodworth, D A; Lawendy, N; Friedman, G S; Cohen, R D Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗